Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. Marcus Larsson Ph.D.

Market Cap

5.69 Million SEK

Sector

Healthcare

Website

https://www.amniotics.com

Last Update

2/22/2024, 12:00:00 PM

Description

Amniotics AB (publ) develops, manufactures, and sells stem cell therapies based on mesenchymal stem cells to treat severe life-threatening diseases.

Read More

Overview

Value

1

Growth

24

Health

6

Management

52

Analyst Opinion

51

Total

27

All Scores Out Of 100

Best Features

  • Earnings growth has improved recently
  • Has a low level of debt
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Income is not covering expenditure and investment
  • Earnings are negative
  • There is a history of diluting shareholders
  • Altman-Z score suggests a risk of bankruptcy
  • Does not hold enough liquid assets to cover short term liabilities
  • Poor overall financial health
  • No margin of safety at their current market price
  • Disliked by Twitter users
  • Poor earnings and cashflow growth
  • Dividend could be at risk

Market Peers

AMNI.ST

Key Figures

PE Ratio (TTM)

N/A

Margin Of Safety (DCF)

-538.45%

Revenue Growth (5 Year Average)

0.00%

Ratings Consensus

Neutral

Share Buybacks

-23.07%

Dividend Yeild (TTM)

0.00%

Valuation

Value Score

1

  • Estimated intrinsic-value of NaN undefined SEK is lower than current price ( 2.10 undefined SEK)
  • Free-cashflow-yeild of -348.43% is worse than the market average (4.7%)
  • Margin-of-safety of -538.45% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: N/A

Current Price: 0 SEK

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

N/Ax

Free Cashflow Yeild

-348.43%

PE/Earnings Growth

N/A

Price/Book

4.36x

Growth

Growth Score

24

  • Revenue growth has improved this yeara
  • 5 Year Average Earnings growth of 19.52% is higher than the market average (14.48%)
  • Earnings growth has improved this year
  • Free Cashflow growth has improved this year
  • 5 Year Average Revenue growth of 0.00% is lower than the market average (10.97%)
  • 5 Year Average Free Cashflow growth of -14.51% is lower than the market average (12.35%)

Revenue Growth

0.00%

Earnings Growth

19.52%

Cashflow Growth

-14.51%

Health

Health Score

6

  • Has a low level of debt
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Cashflow is negative
  • Altman-Z score suggests a risk of bankruptcy
  • Assets do not cover liabilities
  • Debt repayments significantly impact cashflow

Altman Z Score

0.00

Piostroski Score

1.00

Debt/Equity

0.00x

Current Assets/Liabilities

0.48x

Free Cashflow/Total Debt

0.00x

Debt/Capital

0.00x

Dividend

Secure Dividend Score

0

  • Long term dividend payout ratio of 0.00% is considered good
  • Payout ratio (TTM) of 0.00% is lower than the average (40%)
  • Dividends have shown growth over the last 5 years
  • Spending a lower percentage of their income on dividends than last 5 years
  • Dividend yeild of 0.00% is less than the market average (1.85%)
  • Very unsafe

Dividend Yeild

0.00%

Dividend Growth

0.00%

Payout Ratio (Earnings)

0.00%

Payout Ratio (Cashflow)

0.00%

Management

Management Score

52

  • Has issued new shares to finance growth when share price is high
  • Return-on-capital-employed of -11.19% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of -1078.26% is lower than the market average (15%)

Average Buybacks/Dilution

-23.07%

Recent Buybacks/Dilution

N/A

5 Year Price Volitility

103.07%

Return On Assets

-106.65%

Return On Capital Employed

-11.19%

Return On Equity

-1078.26%

Return On Free Cashflow

N/A

Return On Investments

N/A

Social Sentiment

Social Sentiment Score

0

Twitter Sentiment

N/A

Stocktwits Sentiment

N/A

Analysts

Analyst Opinion

51

  • Ratings consensus is Neutral

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Amniotics AB (publ)

Currency

SEK

Beta

0.705966

Vol Avg

2252153

Ceo

Mr. Marcus Larsson Ph.D.

Cik

Cusip

Exchange

Stockholm Stock Exchange

Full Time Employees

14

Industry

Biotechnology

Sector

Healthcare

Ipo Date

2021-07-06

Address

ScheelevAegen 2

City

Lund

State

Country

SE

Zip

22381

Phone

46 7 23 27 85 20

Analysis Last Updated

2/22/2024, 12:00:00 PM

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies